Welcome to LookChem.com Sign In|Join Free
  • or
6-[3,5-bis(3-trifluoromethyl)benzyl]-5-ethyl-2-thiouracil is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

959635-23-5

Post Buying Request

959635-23-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

959635-23-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 959635-23-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,9,6,3 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 959635-23:
(8*9)+(7*5)+(6*9)+(5*6)+(4*3)+(3*5)+(2*2)+(1*3)=225
225 % 10 = 5
So 959635-23-5 is a valid CAS Registry Number.

959635-23-5Relevant academic research and scientific papers

Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors

Wang, Yue-Ping,Chen, Fen-Er,De Clercq, Erik,Balzarini, Jan,Pannecouque, Christophe

experimental part, p. 1016 - 1023 (2009/09/29)

A series of new 5-alkyl-2-benzylsulfanylpyrimidin-4(3H)-ones (5a-y) bearing different substituted arylmethyl moieties at the C-6 position of the pyrimidine core have been synthesized and evaluated for their in vitro activities against HIV-1 and HIV-2 in MT-4 cell cultures. The majority of the title compounds showed moderate to good activities against HIV-1 with an IC50 range from 6.67 μM to 0.12 μM. Among them, 6-(3,5-dimethylbenzyl) analogue 5q exhibited the most potent anti-HIV-1 activity (IC50 = 0.12 μM, SI > 2642), which was about 40-fold more active than the reference compounds 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine (HEPT) and 2′,3′-dideoxyinosine (DDI). The structure-activity relationships (SARs) of these new congeners were further discussed.

Synthesis and antiviral evaluation of 6-(trifluoromethylbenzyl) and 6-(fluorobenzyl) analogues of HIV drugs emivirine and GCA-186

El-Brollosy, Nasser R.,Sorensen, Esben R.,Pedersen, Erik B.,Sanna, Giuseppina,La Colla, Paolo,Loddo, Roberta

, p. 9 - 19 (2008/09/21)

The present study describes the synthesis and antiviral evaluation of a series of novel 6-(3-trifluoromethylbenzyl) and 6-(fluorobenzyl) analogues of the HIV drugs emivirine and GCA-186. The objective was to investigate whether the fluoro or trifluoromethyl substituents could lead to an improved antiviral activity against HIV-1 wild type and mutants resistant to non-nucleoside RT inhibitors. The biological test results showed that the most of theses compounds showed good activity against wild type HIV-1. Among them, compound 1-(ethoxymethyl)-6-(3-fluorobenzyl)-5-isopropyluracil (9i) showed the largest inhibitory potency (EC50 = 0.02 μM), resulting equally potent than emivirine against wild type HIV-1. Furthermore, compound 9i showed marginal better activity against resistant mutants than emivirine. The key steps in the synthesis of the target compounds were either reaction of an appropriate β-keto ester with thiourea or a cross-coupling reaction of 6-chloro-2,4-dimethoxypyrimidines with benzylic Grignard reagents.

Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Wang, Yue-Ping,Chen, Fen-Er,De Clercq, Erik,Balzarini, Jan,Pannecouque, Christophe

, p. 3887 - 3894 (2008/12/20)

A novel series of 2-arylcarbonylmethylthio-6-arylmethylpyrimidin-4(3H)-ones have been synthesized and evaluated for in vitro anti-HIV activities in MT-4 cells. Most of these new compounds showed moderate to potent activities against wild-type HIV-1 with a

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 959635-23-5